Showing 1021-1030 of 3281 results for "".
Superficial Radiation for Keloids: SRT-100 in Practice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/superficial-radiation-for-keloids-srt-100-in-practice/19040/Keloids are common. Certain patients, especially patients of color, are more prone to the development of keloids in certain locations, especially areas such as the chest, back, and other areas. Most studies that show that keloids can occur in up to 90 percent of cases when they're excised. The use oAttendees describe Cosmetic Surgery Forum
https://practicaldermatology.com/topics/practice-management/attendees-describe-cosmetic-surgery-forum/19179/Cosmetic Surgery Forum is a discussion-based symposium for dermatology and skin care professionals from across the country. Watch this video of attendees who describe their experiences and the knowledge they took away from the conference. For more information, visit www.cosmeticsurgeryforum.comVerisante
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/verisante-/19449/News Reel on Vancouver, BC based Verisante discussing the company's partnership with BCCA (British Columbia Cancer Agency) to develop a new product for early skin cancer detection.Analyzing the Overlap Between Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/analyzing-the-overlap-between-atopic-dermatitis-prurigo-nodularis-and-chronic-spontaneous-urticaria/50877/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, is joined by Editorial Board member Jason E. Hawkes, MD, MS, FAAD, to discuss three different immune-mediated inflammatory skin conditions and how understanding their mechanisms can inform optimal treatment, based on the InternationalA Closer Look at OX40 Pathway Modulation
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/a-closer-look-at-ox40-pathway-modulation/50890/Walter Liszewski, MD, talks with Matthew Zirwas, MD, about the potential therapeutic applications, based on the article “Targeting the OX40-OX40L pathway: A new era in atopic dermatitis management by T-cell rebalancing,”1 as well as the risks of therapies targeting the OX40 pathway.Advocacy and Research
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/advocacy-and-research/36479/The latest news and updates, plus Harrison Nguyen, MD, MBA, MPH, FAAD, discusses addressing barriers to maximizing biologics for psoriasis, and Mark Lebwohl, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about some of the latest research he has been involvDermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For thHow New Molluscum Contagiosum Treatments Will Boost QoL and Limit Infection
https://practicaldermatology.com/topics/pediatric/how-new-molluscum-contagiosum-treatments-will-boost-qol-and-limit-infection/20244/Adam Friedman, MD, George Washington School of Medicine discusses the first FDA-approved nitric-oxide based drug in dermatology plus other recent approvals that he believes will make patients lives much easier and reduce the continuity of this condition.DermWireTV: Birch Triterpenes Gel Gets FDA Approval for EB, VTE Risk is Lower in Patients with AD, and Are Topical Steroids Affecting Bone Health?
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-birch-triterpenes-t-gel-gets-fda-approval-for-eb-vte-risk-is-lower-in-patients-with-ad-and-are-topical-steroids-affecting-bone-health/20233/A birch bark extract topical from Chiesi Global Rare Diseases represents the latest in treatment approvals for epidermolysis bullosa. Patients with atopic dermatitis may have a decreased risk for developing venous thromboembolism. Commonly prescribed topical steroids may raise some patients' risk foPreventing AD in High-Risk Infants
https://practicaldermatology.com/topics/atopic-dermatitis/preventing-ad-in-high-risk-infants/20223/Early initiation of short-term emollient use, especially one that contains colloidal oatmeal, can improve skin barrier function and slash the chances of developing atopic dermatitis in high-risk infants. Paul Horowitz, MD, a pediatrician in Valencia, CA, shares highlights from his talk on the STOP-A